

KIRSTEN E. GILLIBRAND
NEW YORK



UNITED STATES SENATOR

September 1, 2015

Dear Friends,

I am proud to recognize this month of September as Charcot-Marie-Tooth Awareness Month. Charcot-Marie-Tooth is a rare disease also known as CMT which affects 1 in 2500 patients in the United States. While there is no cure for CMT, progress is being made through the efforts of organizations like the Hereditary Neuropathy Foundation.

Over nearly fifteen years, the impact of the Hereditary Neuropathy Foundation has continued to grow. Through its partnerships with leading companies, advanced drugs are being developed to treat CMT. I am grateful for the community of support the Hereditary Neuropathy Foundation has established. By building a robust patient registry to support clinical trials for potential treatment, the Foundation has provided opportunities for many individuals to receive possibly life changing treatment.

The effects of Charcot-Marie-Tooth disease significantly impacts the lives of individuals and families of those affected. Greater awareness is needed to address this crisis and increase research and testing trials. It is clear that early and accurate diagnosis of CMT is critical to improving the quality of life for those with CMT. It is my hope that our collective advocacy and greater awareness will increase global awareness of this disease.

During Charcot-Marie-Tooth Awareness Month, I send my best wishes to all those affected.

Sincerely,

A handwritten signature in blue ink that reads "Kirsten Gillibrand". The signature is fluid and cursive.

Kirsten Gillibrand
United States Senator